In Alzheimer disease, which neurotransmitter system is most severely depleted and forms the basis for cholinesterase inhibitor therapy in mild-to-moderate cognitive impairment?

Explanation

## Cholinergic Deficit in Alzheimer Disease **Key Point:** The cholinergic system, particularly neurons in the basal forebrain (nucleus basalis of Meynert), undergoes selective and severe degeneration in Alzheimer disease. This loss of acetylcholine (ACh) contributes to cognitive decline and forms the rationale for cholinesterase inhibitor therapy [cite:Harrison 21e Ch 442]. ### Neurochemical Pathology in Alzheimer Disease #### Cholinergic System (Most Affected) - **Nucleus basalis of Meynert** — loses 50–90% of cholinergic neurons in AD - **Acetylcholine (ACh) levels** — markedly reduced in cortex and hippocampus - **Functional consequence** — impaired attention, memory encoding, and executive function - **Therapeutic target** — cholinesterase inhibitors (donepezil, rivastigmine, galantamine) prevent ACh breakdown **High-Yield:** Cholinergic deficit is the most consistent and therapeutically-targetable neurochemical abnormality in mild-to-moderate AD. #### Other Neurotransmitter Changes (Less Specific) | System | Change | Clinical Relevance | | --- | --- | --- | | **Dopaminergic** | Modest loss in ventral tegmental area | Apathy, psychomotor slowing (NOT primary target) | | **Serotonergic** | Variable loss in dorsal raphe | Depression, anxiety (secondary) | | **GABAergic** | Reduced GABA in cortex and hippocampus | Contributes to excitotoxicity | | **Glutamatergic** | Excessive glutamate (excitotoxicity) | Basis for NMDA antagonist (memantine) | ### Therapeutic Implications **Mnemonic: ACE-M for Alzheimer Cognitive Enhancement — Acetylcholinesterase inhibitors + Memantine** 1. **Cholinesterase inhibitors** (donepezil, rivastigmine, galantamine) - Mechanism: Inhibit acetylcholinesterase → ↑ synaptic ACh - Indication: Mild-to-moderate AD - Effect size: Modest slowing of cognitive decline (3–6 months delay) 2. **Memantine** (NMDA receptor antagonist) - Mechanism: Blocks excessive glutamate-mediated excitotoxicity - Indication: Moderate-to-severe AD - Can be combined with cholinesterase inhibitors **Clinical Pearl:** Cholinesterase inhibitors do NOT reverse pathology; they temporarily improve symptom severity by enhancing residual cholinergic function. Psychiatric symptoms (apathy, depression, behavioral changes) may improve modestly with ACh augmentation. ### Why Cholinergic Deficit Matters Psychiatrically - **Apathy** — cholinergic loss in prefrontal cortex - **Attention deficits** — impair insight and judgment - **Memory impairment** — ACh crucial for encoding in hippocampus - **Reduced emotional processing** — cholinergic input to amygdala